Who is sponsoring NCT05412017?

NCT05412017 is sponsored by Cool Aid Community Health Centre.

What drugs are being tested in NCT05412017?

Interventions in NCT05412017: Hepatitis C Point of Care Testing and Treatment.

What condition does NCT05412017 study?

NCT05412017 studies Hepatitis C.

Is NCT05412017 still recruiting?

NCT05412017 is currently completed. Last updated 7 February 2024.

Last reviewed 2024-02-07 · How we verify

NCT05412017: EPIC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

EPIC: Evaluation of Pharmacy-based Identification and Treatment of HCV

Completed NA Last updated 7 February 2024

What this trial tests

NA trial testing Hepatitis C Point of Care Testing and Treatment in Hepatitis C in 200 participants. Completed in 30 July 2023.

Timeline

13 July 2020

Primary endpoint
30 July 2023

30 July 2023

Quick facts

Lead sponsor	Cool Aid Community Health Centre
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	screening
Enrollment	200
Start date	13 July 2020
Primary completion	30 July 2023
Estimated completion	30 July 2023
Sites	1 location across Canada

Drugs / interventions tested

Hepatitis C Point of Care Testing and Treatment

Conditions studied

Hepatitis C — all drugs for Hepatitis C →

Sponsor

Cool Aid Community Health Centre

Who can join

18 and older, any sex, with Hepatitis C. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The research project aims to understand how pharmacies can be involved in the identification and treatment of hepatitis C (hep C). The study will look at the effectiveness of hep C testing and treatment through pharmacies with support from the Cool Aid Community Health Centre (CACHC). The study will also evaluate the readiness of pharmacies to take on these extra tasks at the pharmacy. This information will be used to develop future strategies to better detect, treat and prevent hep C.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

'<i>I just never wanted them to feel uncomfortable</i>': Barriers to pharmacy-based identification and treatment of hepatitis C in Victoria, Canada.
Selfridge M, Barnett T, Lundgren K, Guarasci K, et al · · 2024 · cited 6× · PMID 38746863 · DOI 10.3138/canlivj-2023-0016

Verify or expand the search:

Other recruiting trials for Hepatitis C

Currently open trials in the same condition.

NCT06263829 — HCV Tappt Adherence Study · NA · recruiting
NCT06179498 — Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs · NA · recruiting
NCT06367465 — Feasibility and Acceptability of HCV Treatment in Pregnancy · recruiting
NCT05668780 — Buprenorphine Integration Research and Community Health · NA · active not recruiting
NCT05208697 — Tele-Harm Reduction · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05412017 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cool Aid Community Health Centre
Last refreshed: 7 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05412017.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing